Skip to main content
. Author manuscript; available in PMC: 2016 Apr 3.
Published in final edited form as: J Proteome Res. 2015 Mar 9;14(4):1968–1978. doi: 10.1021/acs.jproteome.5b00068

Figure 6.

Figure 6

Differentially expressed CF peptides between each of two groups among pancreatic cancer, chronic panceatitis, and healthy control samples. The ratios (PC/SR, CP/SR, or N/SR) of each peptide in individual patient serum samples were subjected to nonparametric analysis of the Student’s t test. VCCSA-1, voltage-dependent calcium channel subunit alpha-2/delta-1; CCTNF3, complement C1q tumor necrosis factor-related protein 3; RTPE, receptor-type tyrosine-protein phosphatase eta; MMR1, macrophage mannose receptor 1; CRT2, complement receptor type 2; LOH3, lysyl oxidase homologue 3; A1AC, alpha-1-antichymotrypsin; n* in different peptide sequences means CF modification at asparagine (n). N, healthy controls; CP, chronic pancreatitis; PC, pancreatic cancer; SR, standard reference; * and ** are significant differences at p < 0.05 and p < 0.01, respectively.